eEF2K activity determines synergy to co-treatment of cancer cells with PI3K and MEK inhibitors
收藏官方服务：
资源简介：
Original data from Western blots
应用场景：
创建时间：
2021-07-09
相关数据集
Synergistic effect of the co-administered SIM and DMXAA on B16.F10 cells proliferation in the presence of TAMs.
Synergistic effect of the co-administered SIM and DMXAA on B16.F10 cells proliferation in the presence of TAMs.
NIAID Data Ecosystem70
Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin
In this study we tested 60 epigenetic inhibitors on four DLBCL cell lines to invesitage whether epigenetic reprogramming can induce sensitization towards rituximab and doxorubicin. The exome and trans
NIAID Data Ecosystem40
Fourteen highly predictive synergistic drug combinations in oncology-screen supported by literature.
Fourteen highly predictive synergistic drug combinations in oncology-screen supported by literature.
NIAID Data Ecosystem30
Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2 overexpressing human mammary epithelial cell lines
HER-2 positive breast cancers frequently sustain elevated AKT/mammalian target rapamycin (mTOR) signaling which has been associated with resistance to doxorubicin treatment in the clinic. In our study
NIAID Data Ecosystem70
Figure S1 - Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
To determine the relative IC50 values for KB(A), KLM1(B) and HAY cells (C) the Cell Viability (Cell-Titer Glo) data were normalized where each concentration of enzastaurin was considered ‘100% of cont
NIAID Data Ecosystem30
